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Preeclampsia (PE) affects 3-5 % of pregnant women and may lead to maternal and/or fetal 
death. The main theory of PE is placental ischemia, leading to a dysfunctional placenta and 
clinical signs as hypertension and proteinuria in the mother. The primary aim of the thesis was 
to implement and optimise a method for high-resolution microscopy of placental cryo-
sections. Secondary aims were to compare the morphology, total antioxidant capacity (TAC) 
and the oxidative stress between normal- and preeclamptic placentas. Placental tissue from 
the fetal and maternal side were collected from three normal pregnant women and three 
preeclamptic women. For each patient; eight cryo-sections were prepared, four from each 
side of the placenta. Two were used as negative controls investigated for autofluorescence 
and two were used as positive controls labelled for morphological analysis. Positive controls 
were labelled with CellMaskTM Orange, staining cell membranes and 4’,6-diamidino-2-
phenylidole, dihydrochloride, staining nuclei. The TAC was determined by comparing the 
measured 3-ethylbenzothiazoline-6-sulphonic acid radical scavenging activity to an ascorbic 
acid standard curve. The oxidative stress was determined measuring the malondialdehyde 
content of the samples. Neither the normal nor the preeclamptic samples had 
autofluorescence affecting microscopy of the labelled sections. The method allowed 
visualisation of microscopic placental structures. In preeclamptic sections from the fetal side, 
there seemed to be more syncytial knots than in fetal sections from normal women. Bright 
red structures were detected in sections from the fetal side of preeclamptic samples and were 
not observed in normal sections. Because of their size, they were thought to be extravillous 
vesicles. The collection-, preservation- and labelling method was successfully implemented 
and is well suited for high-resolution microscopy. Although there were not found a significant 
difference in TAC and oxidative stress between normal- and preeclamptic placentas, neither 
on the fetal- or maternal side, the method is suited for placental tissue.  
V 
 
Table of contents 
Introduction ................................................................................................................................ 1 
Placental development and structure .................................................................................... 2 
The placenta in preeclampsia ................................................................................................ 5 
Oxidative stress .................................................................................................................. 6 
Proinflammatory cytokines ................................................................................................ 8 
Endoplasmic reticulum stress ............................................................................................ 8 
Extracellular vesicles .......................................................................................................... 8 
Biological markers in pregnancy and preeclampsia ............................................................... 9 
Fluorescent labelling methods and microscopy .................................................................. 10 
Aims of the study ..................................................................................................................... 12 
Materials and methods ............................................................................................................ 12 
Clinical evaluation ................................................................................................................ 13 
Statistics of baseline information ..................................................................................... 13 
Collection of placental tissue samples ................................................................................. 13 
Morphological study ............................................................................................................ 14 
Preparation of 4× PHEM buffer ........................................................................................ 14 
Storage of placental tissue samples ................................................................................. 14 
Poly-L-lysine coating of cover glasses .............................................................................. 16 
Labelling of cryo-sections ................................................................................................. 17 
Microscopy ....................................................................................................................... 19 
Oxidative stress study .......................................................................................................... 20 
Total antioxidant capacity assay ...................................................................................... 21 
Oxidative stress assay....................................................................................................... 23 
Statistics ........................................................................................................................... 25 
VI 
 
Results ...................................................................................................................................... 25 
Phenotype of the study population ..................................................................................... 25 
Morphological study ............................................................................................................ 26 
Autofluorescence of placental cryo-sections ................................................................... 27 
Placental morphology of the fetal side ............................................................................ 28 
Placental morphology of the maternal side ..................................................................... 32 
Oxidative stress study .......................................................................................................... 35 
Total antioxidant capacity in normal- and preeclamptic placental tissue ....................... 35 
Oxidative stress in normal- and preeclamptic placental tissue ....................................... 37 
Discussion ................................................................................................................................. 38 
Clinical parameters ............................................................................................................... 38 
Implementation and optimisation of methods for morphology studies ............................. 39 
Morphological investigation using high-resolution microscopy .......................................... 41 
Total antioxidant capacity and oxidative stress study ......................................................... 44 
Conclusions ............................................................................................................................... 45 
Future perspectives .............................................................................................................. 46 
References ................................................................................................................................ 47 
Appendix...................................................................................................................................... i 
Appendix A: Consent form ...................................................................................................... i 
Appendix B: Raw data, total antioxidant capacity assay ....................................................... ii 
Appendix C: Raw data, oxidative stress assay ....................................................................... iii 
 
  
 1  
  
Introduction 
Preeclampsia (PE), eclampsia and hemolysis, elevated liver enzymes and low platelet count 
(HELLP) syndrome are pregnancy-related hypertensive disorders, generally characterized by 
new-onset hypertension after 20 weeks of gestation (1). Pregnant women are diagnosed with 
PE when the blood pressure ≥140 mmHg systolic or ≥90 mmHg diastolic, in combination with 
proteinuria. Women affected with PE may also have placental dysfunction or dysfunction of 
maternal organs due to the increased blood pressure (2, 3). Eclampsia and HELLP syndrome 
are severe complications of PE. Eclampsia is characterized by new-onset grand mal seizures, 
whereas HELLP syndrome is characterized by hemolysis, elevated liver enzymes and low 
platelet count (4, 5).  
Worldwide, PE affects 3-5 % of pregnant women (6). About 1 % of the cases are of a severe 
character, meaning that it is necessary to induce delivery preterm to avoid maternal death 
and/or stillbirth (7). PE affects women in both developed and developing countries and can 
occur in all pregnancies (6). Nulliparous women have a greater chance of being affected by PE 
compared to multiparous women, as the maternal immune system develops tolerance to 
paternal alloantigens following prolonged exposure. Men who have fathered a child where 
the pregnancy was complicated by PE has an increased risk of recurrence in later pregnancies. 
An extreme maternal age, either high or low, previous PE, obesity and chronic disease such as 
diabetes mellitus type I, renal disease and chronic hypertension, also increase the risk of being 
affected by PE. Due to the general increase in obesity, chronic disease and the increased age 
of nulliparous women, the incidence of PE is rising (8). 
PE is divided into early-onset and late-onset, depending on whether the symptoms occur 
before or after week 34 (9). Generally, early-onset PE is more severe compared to late-onset 
PE. Regardless of type, PE is a significant risk factor for both maternal and fetal health, both 
during and after pregnancy. PE may have adverse effects such as acute pulmonary edema, 
epilepsy, kidney and liver dysfunction and intrauterine growth restriction (IUGR), in addition 
to other short-term complications during pregnancy (3, 9). Women who have been affected 
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by PE have an increased risk of being affected by cardiovascular diseases later in life (10). This 
also applies to the offspring from pregnancies complicated with PE. 
For these reasons, blood pressure and urine are regularly checked and analysed throughout 
the pregnancy (11). Women diagnosed with PE are carefully monitored for the remaining 
duration of the pregnancy. Currently, there is no cure to the condition, and the treatment 
consists of controlling the hypertension and inducing delivery (12). Whether delivery is 
induced or not, depends on the gestational age and the maternal condition. In late-onset PE, 
the fetus is mature and delivery can safely be induced. In early-onset PE, the fetus is not fully 
mature and the health risk of the woman by continuing the pregnancy is weighed against the 
risk of premature birth. 
Placental development and structure 
During pregnancy, the fetus is contained in the amniotic sack in the uterus, surrounded by 
amniotic fluid (13). The placenta is the organ responsible for nutrient and oxygen transport 
from mother to fetus, including removal of carbon dioxide and other waste products. This 
transport is mediated through the umbilical cord, connecting the fetus to the placenta. 
Therefore, placental structure and function have a vital role in fetal development. 
A normal mature human placenta is discoid shaped (Figure 1A and B), weighing about 
500 g (14, 15). The placenta has a chorionic- and a basal plate, separated by the intervillous 
space (14). Towards the fetus is the chorionic plate with the umbilical cord, which connects 
the fetus to the placenta (Figure 1A). Towards the uterine wall is the basal plate with its 
cotyledons (Figure 1B). Cotyledons are small circular structures and the smallest functional 
unit of the placenta, consisting of a stem villus and the villi branching out from it (15). In total, 
a placenta has 15-28 cotyledons. 
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Figure 1: The macroscopic structure of a term human placenta. A) Fetal side showing amnion and the umbilical cord. 
B) Maternal side with its membrane folded on the side to show the cotyledons. 
Placental development begins with the implantation of the blastocyst, which consists of two 
cell types; the outer trophoblasts and the inner cell mass (Figure 2A) (13). The trophoblasts 
develop into the placenta, whereas the inner cell mass develops into the fetus, and fetal 
membranes. 
Figure 2: Schematic diagram illustrating 
the placental development. A) Placental 
development starts when the blastocyst 
embeds into the endometrial epithelium. 
The blastocyst consists of two cell types; 
the outer trophoblasts and the inner cell 
mass. B) After implantation, the 
trophoblasts differentiate into two cell 
layers, the outer syncytiotrophoblasts and 
the inner cytotrophoblasts. C) The 
cytotrophoblasts proliferate and 
differentiate, thereby thickening the layer 
of syncytiotrophoblasts. Cytotrophoblasts 
secrete proteolytic enzymes, enabling 
syncytiotrophoblasts to send out 
projections towards the endometrium. 
Cytotrophoblasts and extraembryonic 
mesoderm follows the projections. The 
cotyledon is completed when the fetal 
capillaries are formed. 
Implantation starts with the blastocyst adhering to the endometrial epithelium in the 
uterus (13). Thereafter, the trophoblastic cells proliferate and differentiate into outer 
multinucleated syncytiotrophoblasts and inner cytotrophoblasts (Figure 2B). 
Cytotrophoblasts continue to proliferate and differentiate into syncytiotrophoblasts, 
thickening syncytiotrophoblastic layer. Spaces in the syncytiotrophoblastic layer called 
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lacunae are formed. When these fuse at a later stage in the development, the intervillous 
space is formed. Cytotrophoblasts secrete proteolytic enzymes, enabling syncytiotrophoblasts 
to send out projections, allowing the blastocyst to embed in the endometrium and form the 
early chorionic villi. When syncytiotrophoblasts erodes endometrial blood arteries, the 
lacunae are filled with blood. As separate lacunae merge, they form into the intervillous space. 
Cytotrophoblasts and the extraembryonic mesoderm follows the syncytiotrophoblastic 
projections, continuing the development of the chorionic villi (13). At last, fetal blood vessels 
are formed, completing the villi (Figure 2C). Some fetal villi continues to grow towards the 
basal plate and decidua, anchoring it to the basal plate, whereas other fetal villi are free in the 
intervillous space. Figure 3 presents the placental structure when the placental development 
is completed.(16) 
Figure 3: Placental structure. The fetus is 
connected to the placenta through the 
umbilical cord. Towards the fetus is the 
chorionic plate containing fetal blood 
vessels. From the chorionic plate, 
cotyledons emerge into the intervillous 
space, separated by placental septa. 
Nutritious and oxygen rich maternal blood 
is lead into the intervillous space through 
endometrial arteries penetrating the basal 
plate, embedding the cotyledons in 
maternal blood. Nutritious depleted and 
carbon dioxide rich blood is lead out of the 
intervillous space through endometrial 
veins. The figure is retrieved and modified 
from: Moore and Persaud, 1993 (16). 
Endometrial arteries and veins penetrate the basal plate (17). Whereas the arteries supply the 
intervillous space with maternal blood, the veins remove maternal blood. Each stem villus is 
first divided into three to five intermediate villi, which is further branched into 10 to 
12 terminal villi (18). The branching increases the surface of the cotyledon, making the 
nutritional exchange more effective. The insides of the cotyledons are of fetal origin, 
containing fetal capillaries. 
As shown in Figure 4, a cotyledon is defined by three types of differentiated trophoblastic 
cells: syncytiotrophoblasts, cytotrophoblasts and extravillous trophoblasts (17). 
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Cytotrophoblasts define the inner lining, whereas syncytiotrophoblasts define the outer 
lining. Syncytiotrophoblasts are the only cells of fetal origin that are in contact with the 
maternal blood. The fetal capillaries in the core enable nutritional exchange between the 
maternal and fetal circulation by simple diffusion across the syncytium. In this way, the 
placenta also prevents mixing of fetal and maternal blood (19). 
Figure 4: Overview of the cellular structure of a cotyledon illustrating the 
branched structure. The villus is constituted of trophoblasts; an inner layer of 
cytotrophoblasts (CT) and an outer layer of syncytiotrophoblasts (ST). The core 
of the villus is fetal, containing fetal capillaries, which enable nutritional 
exchange between the maternal and fetal circulation by simple diffusion across 
the syncytium. The extravillous trophoblasts (ET) are differentiated invasive 
trophoblasts, that invade the walls of maternal endometrial arteries to increase 
their diameter. Grey matter inside the villi is mesenchymal core. The figure is 
retrieved and modified from: Zeldovich, et al., 2011 (17). 
During the second trimester, the fetal requirement of nutrients are increasing (20). In normal 
pregnancies, extravillous trophoblasts invade the walls of the maternal endometrial arteries 
to increase their diameter, thereby increasing the blood flow to the intervillous space (21).  
The placenta in preeclampsia 
The main theory of the etiology of PE is based on the placenta being ischemic (22, 23). This is 
supported by a study that found that the uteroplacental blood flow is reduced in women 
affected by PE (24). Placental ischemia is thought to occur when extravillous trophoblasts fail 
to increase the diameter of the maternal arteries, leading to a hypoxic placenta. During the 
ischemic period, the blood in the intervillous space has low levels of oxygen and nutrients (6). 
Decreased circulation leads to inflammation and oxidative stress. The placental hypoxia also 
leads to endoplasmic reticulum (ER) stress, release of proinflammatory cytokines and 
extracellular vesicles (EV) (Figure 5). When this occurs, the balance between anti-angiogenic 
and proangiogenic factors is skewed; anti-angiogenic factors increase while proangiogenic 
factors decrease. This leads to manifestation of clinical symptoms such as hypertension, 
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proteinuria, oedema, elevated liver enzymes and IUGR. Therefore, inflammation and oxidative 
stress affect the placental function, as well as fetal development and maternal health during 
pregnancy. 
Figure 5: Schematic illustration of the 
pathophysiology of preeclampsia (PE). Factors 
affecting the physiological transformation of 
the spiral arteries by the trophoblasts are 
genetic factors, abnormal trophoblast-decidua 
interaction and oxidative stress. When this 
occurs, the deep placentation is defective as the 
diameter of the spiral artery fail to increase. Less 
oxygen and nutrient rich blood enter the 
intervillous space, rendering the placenta as 
dysfunctional, causing endoplasmic reticulum- 
and oxidative stress. In addition, more 
proinflammatory cytokines are secreted into the 
maternal circulation by trophoblasts. 
Extracellular vesicles containing micro- and 
nanoparticles are also released into the 
maternal circulation. This leads to the secretion 
of more anti-angiogenic molecules and less 
proangiogenic molecules, activating endothelial 
cells, and thereby causing the clinical 
symptoms. The figure is retrieved and modified 
from: Chaiworapongsa et al., 2014 (6). 
Oxidative stress 
Oxidative stress arises when the production of reactive oxygen species (ROS) exceeds the 
elimination, leading to ROS accumulating in the cell (25). ROS are highly reactive by-products 
of the oxygen metabolism in the cells, produced in different organelles with mitochondria 
being the largest contributor (26). As ROS have highly reactive properties, they can interact 
with central cellular structures, such as proteins, lipids and nucleic acids, thereby affecting 
their function (25). 
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Under normal conditions, there is a balance between the production and elimination of ROS. 
To maintain this balance, cells have different types of antioxidants and anti-oxidative systems 
to eliminate ROS, such as enzymes, peptides, vitamins and proteins (27). Some antioxidants 
are produced by the cells themselves, whereas other must be supplied through the diet. 
Reduced oxidative stress requires a balance between the amount of ROS and the total 
antioxidant capacity (TAC) of the cell or tissue. 
Controlled levels of ROS are essential for normal cell function since ROS function as secondary 
messengers in several signalling pathways (28). These signalling pathways have different 
functions, such as activation of transcription factors, apoptosis and cell differentiation. 
Therefore, ROS should be generated, and the levels regulated for normal placental 
development and function (29). 
Malondialdehyde (MDA) is a degraded lipid product and a well-studied biomarker of oxidative 
stress (30). As the levels of ROS increase, ROS react with surrounding cell membrane lipids to 
give lipid peroxidation products, such as MDA. Therefore, rising levels of MDA indicate 
increasing oxidative stress. By measuring the amount of MDA quantitatively, the oxidative 
stress level of the tissue can be determined. MDA reacts easily with thiobarbituric acid (TBA), 
resulting in a pink coloured adduct that can be measured quantitatively by 
spectrophotometry (27). MDA have been detected both in maternal circulation and placental 
tissue (30). It is shown that pregnant women in general have elevated levels of MDA. In normal 
pregnant women, the MDA level is balanced by increasing the TAC of the tissue, thereby 
eliminating ROS and preventing oxidative stress. Pregnant women affected by PE have higher 
levels of MDA compared to normal pregnant women. However, in women with PE, the TAC 
does not manage to overcome the increased production of ROS, leading to oxidative 
stress (31). 
Long-term and chronic oxidative stress have been shown to contribute to the initiation of 
placental and endothelial dysfunction, in addition to induce inflammation by releasing 
proinflammatory cytokines (28, 32, 33). These mechanisms have a retroactive effect that 
increases the oxidative stress, creating a positive feedback loop. 
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Proinflammatory cytokines 
Compared to normal pregnancies, pregnancies complicated with PE have higher levels of 
tumour necrosis factor (TNF)-α, interleukin (IL)-1β, IL-6 and IL-17, in addition to reduced levels 
of IL-4 and IL-10 (34-38). Among these cytokines, TNF-α, IL-1β, IL-6 and IL-17 are 
proinflammatory, whereas IL-4 and IL-10 are anti-inflammatory. The proinflammatory 
cytokines are present in the maternal circulation, increasing the endothelial permeability 
allowing proteins to leave the circulation and occur in the urine (39). TNF-α increases the 
vasoconstrictor endothelin-1 and reduces the vasodilator nitric oxide, leading to 
hypertension (37, 40). 
Endoplasmic reticulum stress 
The ER is an organelle consisting of several sacks called cisternae. This organelle is responsible 
for protein folding and transport and lipid synthesis. Placental hypoxia leads to an ischaemia-
reperfusion injury in the intervillous space, which can lead to ER stress (41). During ER stress, 
proteins are incorrectly folded, resulting in accumulation of misfolded proteins in the ER. As a 
response to the ER stress, the unfolded protein response (UPR), a collection of signalling 
pathways are activated to overcome the ER stress. If the activation of UPR is not successful, 
the ER stress persists and leads to cessation of cell proliferation and apoptosis (42, 43). When 
trophoblasts undergo apoptosis, microparticles and nanoparticles are released into the 
maternal circulation (44).  
Extracellular vesicles 
EVs are lipid bilayers, ranging from 50 nm to 2 μm, containing cargo such as proteins, lipids 
and nucleic acids from the cell in which they were generated (45). There are two types of EVs 
classified by their size, content and origin: exosomes and microvesicles. Exosomes are 
30 nm-150 nm in size and originate from the endolytic pathway, while microvesicles are 
100 nm-1 μm in size and originate from direct budding or shedding, often in response to 
cellular stress (46).  
EVs are thought to be a way of intercellular communication, where the cells in which the EV 
originated can interact with and change the activity of specific target cells (47). During 
pregnancy, placental cells, mainly the trophoblasts, release EVs to change the activity of 
maternal target cells, thereby altering the maternal physiology to accommodate fetal 
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requirements (47, 48). Such EVs have been found after six weeks of gestation (49). It has been 
proposed that EVs modulate central processes in pregnancy, such as cellular adaptations to 
pregnancy-related physiological changes, regulation of immune responses and migration and 
invasion of placental cells (47).  
Compared to non-pregnant women, pregnant women have higher concentrations of EVs in 
the maternal circulation (50). Pregnant women affected with PE have an even higher 
concentration of EVs in the circulation and increases with disease severity. 
Biological markers in pregnancy and preeclampsia 
Biological markers (biomarkers) are measurable variables present in human tissues, cells or 
fluids that can be used either qualitative or quantitative to assess a person’s physiological 
condition at a given time (51). There are four types of biomarkers; diagnostic, predictive, 
prognostic and therapeutic (52). Diagnostic biomarkers are used to diagnose a disease, 
predictive biomarkers are used to assess the response of a treatment, prognostic biomarkers 
are used to assess the progression of a condition with or without treatment, and therapeutic 
biomarkers are substances that can be used as targets for a therapy. As biomarkers have a 
variety of applications, biomarkers can be various substances found within the human body, 
such as cells, proteins, DNA and RNA (51). 
In all pregnancies, cells and molecules originating from the placenta are shed and secreted 
into the maternal blood stream where they can be detected (53). These factors can either be 
passive, meaning they are a by-product of placental processes, or active, meaning they are 
released to change the maternal physiology to accommodate fetal requirements.  
A biomarker used to confirm pregnancy is human chorionic gonadotropin (hCG), a hormone 
produced by the syncytiotrophoblastic cells in the placenta (54). The levels of hCG increase 
from implantation until week 10, where it peaks, before it drops slightly and stabilizes (54, 
55). The hormone is present and detected in both the maternal circulation and urine. (55). As 
normal nonpregnant women do not produce hCG, the presence of the hormone in the 
maternal urine is a secure way of detecting pregnancy using simple commercial pregnancy 
tests. 
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Generally, both passive and active molecules are thought to be dysregulated during 
pregnancy-related diseases, making it possible to detect these molecules prior to the disease 
onset (53). All pregnancy-related diseases are thought to have several different potential 
biomarkers. In 2004, World Health Organization stated that «… there is no clinically useful 
screening test to predict the development of preeclampsia» (56). Since then, studies have 
found several potential biomarkers for PE, including soluble fms-like tyrosine kinase 1 (sFlt-1) 
and placental growth factor (PGF) (57, 58). 
Fluorescent labelling methods and microscopy 
Fluorescent microscopy is an important tool for examining tissue samples, utilising the ability 
of fluorescent molecules called fluorophores. Fluorophores absorb and emit light at specific 
wavelengths, thereby enabling visualisation of the labelled structures and molecules within 
cells and tissues (59). 
Fluorophores absorb and emit light when their energy state is changed (60). When a photon 
hits a fluorophore, its electrons are excited to a higher energy level from its ground state level 
with lower energy. After a short time, the fluorophore transitions down to a lower energy 
level, releasing energy as vibrations and heat. Thereafter, the fluorophore transitions back to 
ground state level, releasing energy by emitting a photon. Following the principle of energy 
conservation, the incident photon is more energetic than the emitted photon. Each type of 
fluorophore has a characteristic excitation and emission spectra, making them ideal for 
observation in a microscope.  Fluorescence microscopes can be used to detect fluorophores 
and can use different sources such as mercury lamps or lasers to illuminate the samples. The 
released photons are detected by a photodetector such as a camera. As each fluorophore emit 
light at a specific wavelength, different amounts of energy are required to excite them. By 
using different optical filters, it is possible to capture fluorescent light of specific wavelengths, 
making it possible to detect several fluorophores in one sample. Therefore, it is important to 
ensure that the fluorophore emits light of a wavelength that is detectable by the microscope 
that is used. By using fluorophores emitting different wavelengths of light, several structures 
can be visualised in the same section. 
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Deconvolution is a 
computational method 
used to improve images on 
fluorescent microscopes, 
enhancing the resolution 
by removing out of focus 
blur using algorithms (61). 
For this to be done, the 
point spread function 
must be optimised. Optimisation occurs when the refractive index of the immersion oil 
matches the cover glass and is controlled using orthogonal view on individual DV images. 
When symmetrical shapes are obtained (Figure 6), there is an oil match (62). There is an oil 
mismatch when asymmetrical shapes occur, and the immersion oil should be changed as oil 
mismatch can cause reconstruction artefacts. 
Fluorescence microscopy has some disadvantages (60). Over time, fluorophores are 
photobleached, leading to a diminishing fluorescence. Structures within the cells may be 
autofluorescent, which may affect the imaging. Another limitation with conventional 
fluorescence microscopy, such as DV, is the resolution, which is limited by the diffraction of 
light to approximately 200 nm. Ultimately, this is what has led to the development of a new 
subset of fluorescence microscopy called super-resolution microscopy (SRM), allowing clear 
view of nanoscale subcellular structures. 
A subsection within SRM is structured illumination microscopy (SIM), a method using a striped 
illumination pattern projected over the sample in a controlled fashion to improve the 
resolution (63). The Moiré fringes that result on the sample plane allow to visualise small 
details that otherwise would not be visible by the objective lens of the microscope. By 
changing the location of the illumination pattern, different parts of the sample become 
observable. Typically, nine images of an image field are taken to achieve a high-resolution 
image, each one with a specific phase and orientation. A specific algorithm is used to process 
the information, reconstructing an image of the biological sample with a resolution of 
 
Figure 6: Point spread function in orthogonal view when there is an oil match. 
A) How the light looks in the horizontal orientation. B) How the light looks in the 
vertical orientation. Villegas, 2018 (73). 
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approximately 100 nm, increasing the resolution two-fold compared to DV. The PSF must also 
be checked in orthogonal view on individual SIM images to ensure oil matching. 
Aims of the study 
The primary aim of this thesis was to implement and optimise a collection and labelling 
method to better examine placental cryo-sections using high-resolution microscopy. The 
secondary objectives were to: 
• Investigate morphological differences of the placenta from normal pregnant women 
and women affected with preeclampsia using high-resolution microscopy techniques 
for cryo-sections. 
• Compare oxidative stress and total antioxidant capacity levels in placental tissue 
samples from normal pregnancies, and pregnancies complicated with preeclampsia 
using malondialdehyde assay and the ABTS scavenging activity of ascorbic acid, 
respectively. 
Materials and methods 
This study includes the collection, preparation and analysis of placental tissue samples from 
patients at the Department of Obstetrics and Gynaecology, University Hospital of Northern 
Norway (UNN). The study was approved by the Regional Committee for Medical and Health 
Research Ethics in Northern Norway (#2019/438) and Pasientvernombudet at UNN (reference 
number 2201). The research was performed following principles of the Helsinki 
declaration (64). All participants signed an informed consent form (Appendix A). The dignity 
of all participants was prioritized, and the study was observatory without inconvenience and 
discomfort for the participants. Collection of placental samples were performed after delivery 
and did not affect patient care. None of the research collaborators had any conflict of interest. 
In this study, tissue from three normal- and three preeclamptic placentas were collected. 
Inclusion criteria for women with PE were new-onset, persistently elevated blood pressure 
(systolic blood pressure ≥140 mm Hg or a diastolic blood pressure ≥90mm Hg) and proteinuria 
after 20 weeks of gestation (65). 
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Clinical evaluation 
The clinical evaluation was performed by the doctors at the Department of Obstetrics and 
Gynaecology, UNN, following the Norwegian guidelines for diagnosis and treatment of PE (65). 
Pregnant women suspected of being affected with or were diagnosed with PE were closely 
monitored and followed up. 
Statistics of baseline information 
Clinical data were analysed using IBM SPSS Statistics 21. Continuous variables are presented 
as mean ± standard deviation or median (range); categoric variables are presented as 
numbers (%). Differences between groups were tested using the Student’s T-test for 
parametric data and with the Mann-Whitney U test or 2test for nonparametric and 
categorical variables. A p-value lower than 0.05 was considered as statistically significant. 
Collection of placental tissue samples 
Placental tissue samples from normal pregnant women and women affected with PE were 
collected from the Department of Obstetrics and Gynaecology at UNN. Chemicals used for 
sample collection are listed in Table 1. 
Table 1: Chemicals used for collection of placental tissue samples. 
Chemicals Manufacturer Reference Purpose 
Sodium chloride 
(9 mg/mL) 
Fresenius Kabi AG 826968 
Rinse the collected 
tissue of blood 
 
The placental samples were obtained 
within 30 min after delivery. All tissue 
samples were collected approximately 
three cm from the umbilical cord (Figure 
7). Two tissue samples were collected for 
each study; one originating from the fetal 
side, and one originating from the 
maternal side. 
The tissue samples were acquired by 
cutting through the placenta to obtain a 
piece containing both the maternal- and 
 
Figure 7: Image of a placenta showing where the tissue 
samples were obtained. The image shows the fetal side with the 
umbilical cord. Tissue samples were taken approximately three 
cm from the umbilical cord. 
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fetal side (66). Thereafter, the piece was further cut to separate the maternal and fetal sides. 
The tissue pieces were rinsed for blood using 9 mg/mL sodium chloride and collected in 
separate tubes on ice for further preparation and storage. 
Morphological study 
Preparation of 4× PHEM buffer 
PIPES-HEPES-EGTA-Magnesium sulphate (PHEM) is a no-toxic buffer used for 
immunocytochemical studies as it gives better ultrastructural preservation (67). It is often 
used for electron microscopy studies and was therefore used for temporarily preservation of 
the tissue pieces prior to fixation. Chemicals used for buffer preparation are listed in Table 2. 
Table 2: Chemicals used to make the 4× PIPES-HEPES-EGTA-Magnesium sulphate (PHEM) buffer. 
Chemicals Manufacturer Reference Purpose 
EGTA1 Sigma-Aldrich E4378-100G Used in PHEM 
HEPES2 VWR Chemicals 441476L Used in PHEM 
PIPES3 Sigma P6757-500G Used in PHEM 
Magnesium sulphate Sigma-Aldrich M7506-500G Used in PHEM 
5 M sodium 
hydroxide 
Sigma-Aldrich 30620-1KG-R Used in PHEM 
1 Ethylene glucol tetraacetic acid (ethylene glycol-bis (β-aminoethyl ether)-N,N,N’,N’-tetraacetic acid) (EGTA) 
2 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) 
3 1,4 piperazine bis (2-ethanosulfonic acid) (PIPES) 
First, 36.28 g of 1,4 piperazine bis (2-ethanosulfonic acid) (PIPES) were added to 225 mL ddH2O 
and the pH was adjusted to 6.9 using 5 M sodium hydroxide. Then, 13 g of 4-(2-hydroxyethyl)-
1-piperazineethanesulfonic acid (HEPES), 7.6 g of ethylene glucol tetraacetic acid (ethylene 
glycol-bis (β-aminoethyl ether)-N,N,N’,N’-tetraacetic acid) (EGTA) and 1.98 g of magnesium 
sulphate were added and the volume was adjusted to 250 mL using ddH2O. At last, the pH was 
adjusted to 6.9 using 5 M sodium hydroxide.  
Storage of placental tissue samples 
The collected tissue was fixed over night, immersed in gelatine and transferred to sucrose to 
prevent crystallisation during freezing. At last, the tissue was mounted on specimen carriers 
and frozen in liquid nitrogen. Equipment used for sample fixation and storage is listed in Table 
3 and chemicals in Table 4. 
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Table 3: Equipment used to store collected placental tissue samples. 
Equipment Manufacturer Reference Purpose 
VWR Digital 
Incubator 
VWR - Liquify gelatine 
Specimen carriers Leica 167001950 
Assembly of tissue 
pieces for storage 
B7925 Tube Rotator Agar Scientific - 
Ensure the tissue 
were immersed in 
gelatine and sucrose 
Table 4: Chemicals used to store collected placental tissue samples. 
Chemicals Preparation Manufacturer Reference Purpose 
Fixative 
15 mL 0.2 M PBS1, 
7.5 mL 8 % FA2 
diluted in 
4× PHEM3, 
7.5 mL ddH2O 
-  - 
Fixate tissue and 
preserve tissue 
morphology 
FA (8 %) 
7 mL 16 % FA in 
7 mL 1x PHEM 
- - Used in fixative 
FA (16 %) 
16 g FA in 
100 mL ddH2O 
- - 
To further dilute to 
8 % FA 
FA - Sigma-Aldrich 
158127-
500G 
Prepare 16 % FA 
Gelatine 
(12 %) 
12 g gelatine 
diluted in 







spaces and cavities 
in the tissue 
PBS (0.2 M) 
10 mL 1 M PBS in 
40 mL ddH2O 
Oxoid LTD BR0014G Used in fixative 
PBS (1 M) 
1 g PBS in 
1 L ddH2O 
Oxoid LTD BR0014G Washing 
PHEM (1×) 
10 mL 4× PHEM 
diluted in 




dehydration of the 
tissue 
PHEM (4×) - - - Dilute to 1× PHEM 
Sucrose 
(2.3 M) 
342 g sucrose 
diluted in 





1 Phosphate buffered saline (PBS) 
2 Formaldehyde 
3 PIPES-HEPES-EGTA-Magnesium sulphate buffer (PHEM) 
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The collected tissue samples were transferred to 5 mL of 1× PHEM. Thereafter, the tissue 
samples were cut in pieces of 1 mm3, immersed in 5 mL of fixative and incubated at 4 °C over 
night. 
After overnight incubation, the tissue samples were washed 2×5 min in 
5 mL of 1 M phosphate buffered saline (PBS) followed by incubation in 1 mL 12 % gelatine in 
a tube rotator for 1 h at 37 °C. The tissue samples were then transferred to 1 mL 
of 2.3 M sucrose on ice and incubated in a tube rotator at 4 °C over night.  
The tissue samples were assembled on specimen carriers before being frozen in liquid 
nitrogen. The specimen carrier was applied 2.3 M sucrose before a tissue sample was 
transferred onto it and frozen in liquid nitrogen. For each patient, five specimen carriers were 
prepared from each side of the placenta. The unassembled tissue samples were preserved in 
2.3 M sucrose and frozen in liquid nitrogen with the assembled tissue samples. 
Poly-L-lysine coating of cover glasses 
To make cells adhere to the cover glass and avoid detachment during labelling and washing, 
cover glass was coated with poly-L-lysine. Equipment used to coat cover glass is listed in Table 
5 and chemicals in Table 6. 
Table 5: Equipment used to coat cover glasses with poly-L-lysine. 
Equipment Manufacturer Reference Purpose 
13 mm #1.5 Cover 
glass 
VWR 631-0150 - 
Table 6: Chemicals used to coat cover glasses with poly-L-lysine. 












Cover glasses were cleaned using ethanol, rinsed with ddH2O and air dried on filter paper. 
Thereafter, 30-50 µL of 0.2 mg/mL poly-L-lysine were pipetted in the centre of the cover glass 
and settled for 30 min in a moist chamber. The cover glasses were rinsed with ddH2O and 
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dried on filter paper over night at room temperature. Poly-L-lysine coated cover glasses were 
stored in dust-free dishes at room temperature until use. 
Labelling of cryo-sections 
Ultrathin cryo-sections were prepared using the Tokuyasu method (68). The Tokuyasu method 
is a gentle method solidifying the tissue by freezing and cutting cryo-sections. From each 
placental sample, eight cryo-sections were prepared; four from the fetal side of the placenta 
and four from the maternal side of the placenta. From each side, two cryo-sections were 
prepared as negative controls for investigation of autofluorescence, and two cryo-sections 
were stained with CellMaskTM Orange (CMO) and 4’,6-diamidino-2-phenylidole, 
dihydrochloride (DAPI) to visualize cellular structures. Equipment used for labelling is listed in 
Table 7 and chemicals in Table 8. 
Table 7: Equipment used to label the placental cryo-sections. 






Nail polish - - 
Seal the edge of the 
mounted cover glass 
Poly-L-lysine coated 
cover glass with 
tissue sections 
- - - 
Six-edged nut - - 
Ensure the cover 
glass was in level 
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Table 8: Chemicals used to label the placental cryo-sections. 
Chemicals Preparation Manufacturer Reference Purpose 
BSA1 (1 %) 
0.5 g BSA in 
50 mL 1 M PBS2 
Sigma A8022 Blocking 
CMO3 (250 ng) 
0.5 μL CMO in 
999.5 μL 1 M PBS 
ThermoFisher  C10045 
Staining cell 
membranes 
DAPI4 (5 ng) 
1 μL DAPI in 







cellulose (1 %) 
250 μL 2% methyl 
cellulose in 






cellulose (2 %) 
2 g methyl cellulose in 






1 % methyl 
cellulose 
PBS (1 M) 1 g PBS in 1 L ddH2O Oxoid LTD BR0014G 
Washing and 
dilution of CMO 
and DAPI 





342 g sucrose diluted 
in 100 mL ddH2O 
Sigma-Aldrich 16104-1KG 
Prepare methyl 
cellulose (1 %) 
1 Bovine serum albumin (BSA) 
2 Phosphate buffered saline (PBS) 
3 CellMaskTM Orange (CMO) 
4 4’,6-diamidino-2-phenylidole, dihydrochloride (DAPI) 
For each patient sample, eight ultrathin cryo-sections (1 µm) were prepared using the 
Tokuyasu method. Four sections originated from the fetal side of the placenta and four 
sections originated from the maternal side of the placenta. The sections were prepared on 
separate poly-L-lysine-coated cover glasses and covered with 1 % methyl cellulose. Sectioning 
was performed by engineer at the Facility for Advanced Microscopy, UiT – The Arctic 
University of Norway. 
All sections were cooled on a parafilm covered metal plate on ice for 10 min and washed 
3×7 min with 100 µL of 1 M PBS. Between each wash, the sections were prevented from 
drying by adding new PBS immediately after removing the previous wash, using absorbent 
paper. Following washing, the metal plate with the sections were taken off the ice, placed on 
bech and blocked in 100 µL of 1 % bovine serum albumin (BSA) for 30 min. Thereafter, the 
sections were washed 2×5 min in 100 µL of 1 M PBS. 
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From each side of the placenta, two sections were labelled. To label the sections, 100 µL of 
CMO (250 ng) were added, and the sections were incubated for 10 min protected from light. 
The sections were then washed 2×5 min in 100 µL of 1 M PBS as previously described. 
Thereafter, 100 µL of DAPI (5 ng) were added and the sections were incubated in the dark for 
5 min.  At last, the sections were washed 3×5 min in 100 µL of MilliQ-water and mounted. 
The remaining two sections were prepared as unlabelled negative controls. These were 
washed 3×5 min with 100 µL of ddH2O and mounted as described for the labelled sections. 
Mounting was performed by adding one small drop of Prolong Gold in the centre of a glass 
slide. The cover glass was immediately placed on top with the tissue section facing the 
mounting medium. If air bubbles appeared, the cover glass was carefully tapped with a plastic 
tweezer. A six-edged nut was placed on top of the cover glass to ensure that it was level. 
Thereafter, the sample was incubated for 1 h protected from light before the edge of the cover 
glass was sealed using nail polish. The mounted sections were stored at 4 °C, protected from 
light. 
Microscopy 
The unlabelled negative controls were only inspected for autofluorescence using the 
DeltaVision Elite High-resolution Microscope (DV), whereas the labelled slides were imaged 
using both the DV and the DeltaVision OMX V4 Blaze (OMX) microscopes. SoftWoRx and Fiji 
were used to reconstruct and process the images, respectively. Equipment used for 
microscopy is listed in Table 9 and chemicals in Table 10. 
Table 9: Equipment used for microscopy of the prepared tissue sections. 




GE Healthcare - 
Localize the sample 
and ROI1 
DeltaVision OMX V4 
Blaze (OMX) 
GE Healthcare - Examine ROI 
SoftWoRx GE Healthcare - 
Image 
reconstruction 
Fiji Fiji Contributors - Image processing 
1 Region of interest (ROI) 
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Table 10: Chemicals used for microscopy of the prepared tissue sections. 
Chemicals Manufacturer Reference Purpose 
Cargille Laser Liquid 
Code 5610 (1.514) 
GE Healthcare 20130 
Optimize the PSF1 on 
the OMX2 
Cargille Laser Liquid 
Code 5610 (1.516) 
GE Healthcare 20130 
Optimize the PSF on 
the OMX 
Cargille Laser Liquid 
Code 5610 (1.518) 
GE Healthcare 20130 
Optimize the PSF on 
the OMX 
Ethanol (100 %) - - 
Clean the 
microscope slides 
1 Point spread function (PSF) 
2 DeltaVision OMX V4 Blaze (OMX) 
Prior to microscopy, the slide was cleaned using hand soap and water, carefully dried and 
cleaned with 100 % ethanol. The unlabelled sections were only checked for autofluorescence 
using the DV microscope at 10× magnification. The labelled sections were localized using the 
DV microscope at 10× magnification, gradually increasing the magnification to 
20× magnification to find regions of interest (ROI). Coordinates of the ROIs were used to find 
the same regions on the OMX to further investigate them at 60× magnification with immersion 
oil. To ensure that the refractive index of the oil matched the cover glass, the PSF of single 
emitters was observed in orthogonal view. If symmetrical shapes were not obtained, the oil 
was changed accordingly. 
During microscopy, the images were reconstructed using SoftWoRx. After microscopy, the 
images were processed using Fiji.  
Oxidative stress study 
The tissue samples were collected at different times and were stored at -70 °C until 
measurement. On the day of analysis, the samples were thawed, partly dried with tissue 
paper, weighed and homogenised by sonication. Equipment used for tissue homogenisation 
is listed in Table 11 and Table 12. 
Table 11: Equipment used to homogenise the placental samples. 




Spin down cell 
debris 
Branson Sonifier 250 Branson Ultrasonic - 
Homogenize the 
tissue 
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Table 12: Chemicals used to homogenise the placental samples. 
Chemicals Preparation Manufacturer Reference Purpose 
PBS1 Dulbecco 
(0.1 M) 
10 mL 1 M PBS 
Dulbecco in 




1 Phosphate buffered saline (PBS) 
After being transferred to ice, the samples were frozen at -70 °C for long-time storage. When 
enough samples were collected, the oxidative stress and TAC of all samples were measured 
simultaneously to ensure equal conditions. 
The frozen placental samples were thawed for an hour at room temperature. The samples 
were partly dried with tissue paper and 0.2-0.4 g sample were weighed and transferred to 
separate tubes. Each sample was added 0.1 M PBS Dulbecco with the ratio of 
0.5 mL/100 mg sample. All samples were sonicated separately with a probe sonicator 
(30 cycles/30 sec) and centrifuged at 1500×g for 20 min at 4 °C. From each sample, 
2 mL supernatant was transferred to new tubes and kept at 4 °C over night. 
Total antioxidant capacity assay 
The TAC of the placental samples was measured using 2,2’-azino-bis(3-ethylbenzothiazoline-
6-sulphonic acid) (ABTS) radical scavenging activity by the antioxidant molecules in the tissue 
sample (69). To determine the antioxidant content in the tissue samples, the optical density 
at 730 nm wavelength (OD730) of each tissue sample after the reaction with ABTS radicals was 
compared to a standard curve generated using ascorbic acid (a vitamin C equivalent). The 
intensity of the green colour of the ABTS radicals decreases as the amount of ABTS radicals is 
reduced, showing the TAC in the samples. Raw data is presented in Appendix B. Equipment 
used for TAC measurement is listed in Table 13 and chemicals in Table 14. 
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Table 13: Equipment used to measure the total antioxidant capacity (TAC) of the placental samples. 




Agilent Technologies - Measure OD730 
Beckman Microfuge 
11 
Beckman - Centrifuge 
Semi-Micro Cells Agilent Technologies - 
Cuvette used to 
measure optical 
density (OD7301) 
UV visible system 
(software) 
Agilent Technologies - 
Visualize the 
measurement 
1 Optical density at 730 nm wavelength (OD) 
Table 14: Chemicals used to measure the total antioxidant capacity (TAC) of the placental samples. 
Chemicals Preparation Manufacturer Reference Purpose 
ABTS1 (7.4 μM) 
4.06 mg ABTS in 






100 μL 100 mg/mL 
ascorbic acid in 








9.2 mg ascorbic acid in 










200 μL 1 mg/mL ascorbic 










0.70 mg potassium 
peroxodisulfate in 




1 2,2’-azino-bis(3-ethylbenzothiazoline-6-sulphonic acid) (ABTS) 
ABTS radicals were generated by mixing 3 mL 7.4 μM ABTS with 3 mL 2.6 μM potassium 
peroxodisulfate, followed by a 24 h incubation protected from light at room temperature to 
obtain dark green ABTS radicals. The green ABTS radicals were diluted with 200 mL ddH2O to 
achieve an approximate OD730 of 0.7 for the ABTS radicals measuring with a UV 
spectrophotometer. To set reference on the UV spectrophotometer at OD730, 600 μL ddH2O 
was used. All measurements were made using a 700 μL cuvette. 
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Ascorbic acid was prepared as a stock solution of 10 mg/mL and diluted 100 times to prepare 
a standard solution of 100 μg/mL, as shown in Table 14. From the standard solution, 140, 120, 
100, 80, 60, 40, 20, 10 and 0 μL were diluted to 1 mL with ddH2O to make the following 
standard concentrations: 14, 12, 10, 8, 6, 4, 2, 1 and 0 μg/mL, respectively. For each standard 
concentration, three independent measurements were taken. From each standard 
concentration, 300 μL was mixed with 300 μL ABTS radicals and incubated for 30 min at room 
temperature. After incubation, OD730 of each sample was measured with the UV 
spectrophotometer.  
When the measurements of the standard curve were completed, 1 mL tissue lysate was 
transferred to a new tube and centrifuged at 10 000×g for 20 min. Three independent 
measurements for each placental sample were taken. To measure TAC for the tissue samples, 
10 μL suspension (equivalent to 1 mg tissue), 290 μL ddH2O, and 300 μL ABTS radicals were 
mixed and incubated for 30 min. After the incubation, the OD730 of each sample was measured 
with a UV spectrophotometer. The TAC of the samples was determined by comparing the 
OD730 of each sample to the ascorbic acid standard curve.  
Oxidative stress assay 
The oxidative stress in the placental tissue samples were determined by measuring their MDA 
content. This was performed using the Lipid Peroxidation (MDA) Assay kit, with some 
adjustments from the manufacturer’s protocol to adapt it to placental samples (70). To 
determine the MDA content in the tissue samples, the optical density at 532 nm 
wavelength (OD532) of each sample was compared to a standard curve generated using MDA. 
As the intensity of the pink colour increases, the concentration of MDA increases, showing the 
oxidative stress in the samples. Raw data is presented in Appendix C. Equipment used for MDA 
measurements is listed in Table 15, kits in Table 16 and chemicals in Table 17. 
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Table 15: Equipment used to measure the oxidative stress in the placental samples. 
Equipment Manufacturer Reference Purpose 
Falcon 96-well plate Corning 303572 
Measure MDA 
concentration in 




BioTek Instrument - 
Measure the optical 
density of each well 
Table 16: Kit used to measure the oxidative stress in the placental samples. 
















10 μL 4.17 M MDA 
in 407 μL ddH2O 
To further 
dilute to 





1 Malondialdehyde (MDA) 
2 Thiobarbituric acid (TBA) 
Table 17: Chemicals used to measure the oxidative stress in the placental samples. 
Chemicals Preparation Manufacturer Reference Purpose 
MDA1 standard 
(2 mM) 
20 μL 0.1 MDA 




1 Malondialdehyde (MDA) 
MDA was prepared as a stock solution of 0.1 M, which was diluted to 2 mM as shown in 
Table 17. Various concentrations of MDA were used to make the standard curve; 10, 8, 6, 4, 2 
and 0 μL of 2 mM MDA was diluted to 200 μL with ddH2O to make the following standard 
concentrations of 20, 16, 12, 8, 4 and 0 nM, respectively. From each standard concentration 
of MDA, 200 μL was mixed with 600 μL thiobarbituric acid (TBA). To measure the MDA content 
in the samples, 100 μL (equivalent to 10 mg tissue) of supernatant of each tissue sample was 
mixed with 100 μL lysis buffer and 600 μL TBA. Both the standard and the tissue samples were 
heated in a water bath at 90 °C for 1 h and cooled down on ice for 10 min to obtain a light 
pink-coloured MDA-TBA adduct.  
From the reaction mixture, 200 μL of each standard and tissue sample were transferred to 
two separate wells on a 96-well plate with the layout shown in Figure 8. OD532 for each MDA 
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standard and tissue sample were measured spectrophotometrically by an enzyme-linked 
immunosorbent assay plate reader. 
 
Figure 8: Schematic diagram showing the layout on the 96-well plate. To each well, 200 μL of solution were added. Rows 
B and C contain the different concentrations of the MDA standard, whereas rows D, E, F and G contain the tissue samples. 
“N” denotes samples from a normal placenta, whereas “P” denotes samples from a preeclamptic placenta. “F” denotes 
samples from the fetal side, whereas “M” denotes samples from the maternal side. 
Statistics 
The mean OD730 and OD532 were calculated for the TAC and MDA assays, respectively. The 
mean OD for each of the assays was used to calculate the mean antioxidant 
concentration (µg ascorbic acid/mg placental tissue) and the mean MDA 
concentration (nM MDA). To evaluate the statistical significance of the normal- and 
preeclamptic samples, Student’s T-test was used, and the p-values were determined. A p-
value lower than 0.05 was considered as significant. 
Results 
Phenotype of the study population 
The baseline demographic and clinical characteristics of the study population were routinely 
collected by midwifes and doctors at the Department of Obstetrics and Gynaecology, UNN, 
and is presented in Table 18. The mean proteinuria level in patients with PE was median 
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2 g/L (ranging from 1 to 3 g/L). None of the women included in the study had HELLP syndrome. 
In the preeclamptic group, two women delivered by caesarean section because of an acute 
deterioration of the patient’s condition. One woman in the normal group also had caesarean 
delivery. None of the women who delivered by caesarean section were in labour. The two 
other women in the normal group had vaginal delivery and one in the PE group. In each group, 
one woman had her labour induced. 
Table 18: Selected clinical parameters of the preeclamptic and normal group. The differences were tested using Student’s T-
test for parametric variables and with the Mann-Whitney U test or 2test for nonparametric and categorical variables, as 






Maternal agea 35±2.19 33±0 0.488 
BMI1 before deliverya 23.8±3.50 25.1±1.46 0.752 
Primipara n (%) 2 (66.67) 2 (66.67) 1 
Urine Stix protein (g/L)b 2 (1-3) N/A - 
MAP2 117.78±3.37 91.56±5.32 0.014 
Middle cerebral artery pulsatility indexa 1.32±0.24 1.39±0.02 0.842 
Umbilical artery pulsatility indexa 1.22±0.45 0.90±0.00 0.620 
Gestational age at delivery (weeks)a 34±3.71 40±0.67 0.230 
Caesarean section n (%) 2 (66.67) 1 (33.3) 0.000 
Neonatal birth weight (g)a 2812±965 3512±131 0.512 
Placental weight (g)a 484±107 578±14 0.432 
5 min APGAR score (median range)b 10 (9-10) 10 (10-10) 0.667 
Arterial cord blood pHa 7.26±0.04 7.23±0.07 0.825 
Arterial cord blood Base Excessa (mmol/L) -2.80±1.72 -10.15±0.65 0.048 
Venous cord blood pHa 7.28±0.03 7.28±0.07 0.983 
Venous cord blood Base Excessa (mmol/L) -3.70±2.17 -10.60±0.90 0.097 
1 Body mass index (BMI) 
2 Mean arterial pressure (MAP) 
a Data are given as mean ± standard deviation 
b Data given as median (range) 
One of the women in the PE group had early-onset PE (gestational week 27+3) and was 
admitted over time due to complications of her PE. The baby was premature and was admitted 
to the intensive care unit after delivery. The patient record stated IUGR during pregnancy and 
was found on repeated ultrasound scanning.  
Morphological study 
In total, eight sections were prepared from three normal- and three preeclamptic placental 
tissue samples, four from each side of the placenta. From these, two sections were prepared 
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as negative controls, whereas the other two sections were labelled with a membrane specific 
marker, CMO, and a nucleic acid specific marker, DAPI. Autofluorescence was detected by 
using the DV microscope. ROIs on the labelled sections were detected by using the DV 
microscope, which where further investigated using the OMX microscope. 
Autofluorescence of placental cryo-sections 
The autofluorescence of a normal placenta is presented in Figure 9 at 10× magnification. 
Figure 9A shows the autofluorescence of the fetal side, whereas Figure 9B shows the 
autofluorescence of the maternal side. 
 
Figure 9: Overview images at 10× magnification of unstained cryo-sections of a normal placenta, showing the 
autofluorescence. A) The fetal side of the normal placenta. B) The maternal side of a normal placenta. 
Figure 10 shows the autofluorescence of a preeclamptic placenta at 10× magnification; 
Figure 10A shows the autofluorescence of the fetal side, whereas Figure 10B shows the 
autofluorescence of the maternal side. 
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Figure 10: Overview images at 10× magnification of unstained cryo-sections of a preeclamptic placenta, showing the 
autofluorescence. A) The fetal side of a preeclamptic placenta. B) The maternal side of a preeclamptic placenta. 
Placental morphology of the fetal side 
Representative overview images of a cryo-section from the fetal side of a normal placenta are 
presented in Figure 11. In Figure 11A, the cryo-section is magnified 10×. Figure 11B shows the 
squared region in A at 20× magnification, where fetal villi with syncytiotrophoblasts (ST), fetal 
capillaries (FC) and syncytial knots (SK) are identified. 
 
Figure 11: Cryo-sections of the fetal side of a normal placenta. Cell membranes (red) are stained with CellMaskTM 
Orange and nucleic acids (blue) are stained with 4’,6-diamidino-2-phenylidole, dihydrochloride. A) Overview image at 10× 
magnification. B) The squared area in A at 20× magnification, showing a fetal capillary (FC), syncytiotrophoblasts (ST) 
and a syncytial knot (SK). 
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Approximately the same region is magnified to 60× and the resolution is increased using 
deconvolution as presented in Figure 12A. The squared region in A is enlarged in Figure 12B, 
where a fetal capillary and syncytiotrophoblasts are be identified. 
 
Figure 12: Cryo-sections of the fetal side of a normal placenta. Cell membranes (red) are stained with CellMaskTM Orange 
and nucleic acids (blue) are stained with 4’,6-diamidino-2-phenylidole, dihydrochloride. A) A mosaic using deconvolution. 
B) Enlargement of the squared area in A, showing syncytiotrophoblasts (ST) and a fetal capillary (FC). 
The resolution of a smaller region of the villi is further increased using SIM and is presented 
in Figure 13A. The squared region in A is enlarged and presented in Figure 13B, showing a fetal 
capillary and syncytiotrophoblasts. 
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Figure 13: Cryo-sections of the fetal side of a normal placenta. Cell membranes (red) are stained with CellMaskTM Orange 
and nucleic acids (blue) are stained with 4’,6-diamidino-2-phenylidole, dihydrochloride. A) A mosaic using structured 
illumination microscopy. B) Enlargement of the squared area in A, showing a fetal capillary (FC). 
Representative overview images of a cryo-section of the fetal side of a preeclamptic placenta 
are presented in Figure 14. In Figure 14A, the cryo-section is magnified 10×. In Figure 14B 
shows the squared region in A at 20× magnification, where fetal villi defined by the outer 
syncytiotrophoblasts and fetal capillaries are identified. 
 
Figure 14: Cryo-sections of the fetal side of a preeclamptic placenta. Cell membranes (red) are stained with CellMaskTM 
Orange and nucleic acids (blue) are stained with 4’,6-diamidino-2-phenylidole, dihydrochloride. A) Overview image at 10× 
magnification. B) The squared area in A at 20× magnification, showing fetal capillaries (FC) and syncytiotrophoblasts (ST). 
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Approximately the same region is magnified to 60× magnification and the resolution is 
increased using deconvolution and is presented in Figure 15A. The squared region in A is 
enlarged in Figure 15B, where fetal capillaries and syncytiotrophoblasts are be identified. 
 
Figure 15: Cryo-section of the fetal side of a preeclamptic placenta. Cell membranes (red) are stained with CellMaskTM 
Orange and nucleic acids (blue) are stained with 4’,6-diamidino-2-phenylidole, dihydrochloride. A) A mosaic using 
deconvolution. B) Enlargement of the squared area in A, showing fetal capillaries (FC), syncytiotrophoblasts (ST) and bright 
red structures. 
The resolution of a smaller region of the villi is further increased using SIM and is presented 
in Figure 16A. The squared region in A is enlarged and presented in Figure 16B, showing fetal 
capillaries, syncytiotrophoblasts and brighter red structures. The red structures range from 
about 100 nm to 500 nm in size. 
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Figure 16: Cryo-section of the fetal side of a preeclamptic placenta. Cell membranes (red) are stained with CellMaskTM 
Orange and nucleic acids (blue) are stained with 4’,6-diamidino-2-phenylidole, dihydrochloride. A) A mosaic using 
structured illumination microscopy. B) Enlargement of the squared area in A, showing fetal capillaries (FC), 
syncytiotrophoblasts (ST) and bright red structures. 
Table 19 summarises the structures identified in normal- and preeclamptic sections from the 
fetal side. Fetal capillaries, syncytial knots and syncytiotrophoblasts were found in both the 
normal- and preeclamptic sections, whereas brighter red structures only were identified in 
preeclamptic sections. Comparisons of the preeclamptic sections resulted in the identification 
of the same structures and similar morphology. The same applied for comparisons of the 
normal sections. 
Table 19: Structures visualised in the fetal side of the normal- and preeclamptic placental sections. “+” denotes that the 
structure is found in the sections, whereas “-“ denotes that the structure is not found in the sections. Comparisons of the fetal 






Brighter, red structures - + 
Fetal capillaries + + 
Syncytial knots + + 
Syncytiotrophoblasts + + 
Placental morphology of the maternal side 
Representative overview images of a cryo-section of the maternal side of a normal placenta 
are presented in Figure 17. In Figure 17A, the cryo-section is magnified 10×. Figure 17B shows 
the squared region in A at 20× magnification, where extravillous trophoblasts (ET), maternal 
capillaries (MC) and fetal capillaries are identified. 
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Figure 17: Cryo-section of the maternal side of a normal placenta. Cell membranes (red) are stained with CellMaskTM 
Orange and nucleic acids (blue) are stained with 4’,6-diamidino-2-phenylidole, dihydrochloride. A) Overview image at 10× 
magnification. B) The squared area in A at 20× magnification, showing maternal capillaries (MC), fetal capillaries (FC) and 
extravillous trophoblasts (ET). 
Approximately the same region is magnified to 60× and the resolution is increased using the 
deconvolution and SIM as presented in Figure 18A and B, respectively. In both images, 
extravillous trophoblasts, maternal capillaries and fetal capillaries are identified.  
 
Figure 18: Cryo-section of the maternal side of a normal placenta. Cell membranes (red) are stained with CellMaskTM 
Orange and nucleic acids (blue) are stained with 4’,6-diamidino-2-phenylidole, dihydrochloride. A) A mosaic using 
deconvolution, showing extravillous trophoblasts (ET), fetal capillaries (FC) and syncytiotrophoblasts (ST). B) A mosaic using 
structured illumination microscopy, showing extravillous trophoblasts, fetal capillaries and syncytiotrophoblasts.  
Representative overview images of a cryo-section of the maternal side of a preeclamptic 
placenta are presented in Figure 19. In Figure 19A, the cryo-section is magnified 10×. Figure 
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19B shows the squared region in A at 20× magnification, where extravillous trophoblasts (ET) 
are identified. 
 
Figure 19: Cryo-section of the maternal side of a preeclamptic placenta. Cell membranes (red) are stained with CellMaskTM 
Orange and nucleic acids (blue) are stained with 4’,6-diamidino-2-phenylidole, dihydrochloride. A) An overview image at 
10× magnification. B) The squared area in A at 20× magnification, showing extravillous trophoblasts (ET). 
Approximately the same region is magnified to 60× and the resolution is increased using the 
deconvolution and SIM as presented in Figure 20A and B, respectively. In both images, 
extravillous trophoblasts are identified.   
 
Figure 20: Cryo-section of the maternal side of a preeclamptic placenta. Cell membranes (red) are stained with CellMaskTM 
Orange and nucleic acids (blue) are stained with 4’,6-diamidino-2-phenylidole, dihydrochloride. A) A mosaic using 
deconvolution, showing extravillous trophoblasts (ET). B) A mosaic using structured illumination microscopy, showing 
extravillous trophoblasts (ET). 
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Table 20 summarises the structures identified in normal- and preeclamptic sections from the 
maternal side. Extravillous trophoblasts were found in both normal- and preeclamptic 
sections, whereas maternal capillaries were only found in the normal cryo-sections. 
Comparisons of the preeclamptic sections resulted in the identification of the same structures 
and similar morphology. The same applied for comparisons of the normal sections. 
Table 20: Structures visualised in the maternal side of the normal- and preeclamptic placental sections. “+” denotes that 
the structure is found in the sections, whereas “-“ denotes that the structure is not found in the sections. Comparisons of the 






Extravillous trophoblasts + + 
Maternal capillaries + - 
Oxidative stress study 
Total antioxidant capacity in normal- and preeclamptic placental tissue 
TAC of the tissue samples was determined by measuring the ABTS radical scavenging activity 
by the antioxidants present in the tissue samples. The radical scavenging activity was 
measured spectrophotometrically at 730 nm wavelength and the OD730 of each sample was 
compared to the standard curve of ascorbic acid. 
The standard curve for the antioxidant capacity of ascorbic acid was prepared by measuring 
the ABTS radical scavenging activity by the known concentrations of ascorbic acid, ranging 
from 0–10 ug/mL. The TAC of the tissue samples is expressed as ascorbic acid equivalent 
antioxidant activity guided by the standard curve as  shown in Figure 21.  
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Figure 21: The standard curve showing the ABTS radical scavenging activity of known concentrations of ascorbic acid. 
Results are presented as the mean of three independent measurements. By using linear regression, the equation of the line 
is y=-0.0652x+0.5873 and the regression coefficient (R2) for the line is 0.98. The standard curve was used to determine the 
ascorbic acid equivalent concentration of total antioxidant capacity in the placental tissue samples, using the average 
optical density at 730 nm wavelength of the three independent measurements for each sample.  
Table 21 shows the average OD730, TAC expressed as µg ascorbic acid/mg placental tissue and 
p-value for the normal and- preeclamptic tissue samples, for both the maternal and fetal side. 
The average OD730 was used to calculate the average TAC in the same placental samples using 
the standard curve for ascorbic acid. There is no statistically significant difference between 
the antioxidant capacities of the normal- and preeclamptic placental samples, neither on the 
maternal or the fetal side. 
Table 21: The total antioxidant activity (TAC) of normal- and preeclamptic placental tissue samples. Results are presented 
as the mean of the three normal- and preeclamptic samples, where each sample had three independent measurements. 
Side Sample Average OD730 
TAC (µg ascorbic acid 
equivalent/mg placental 
tissue) ± SD 
p-value 
Fetal 
Normal 0.28623 4.62 ± 0.59271 
0.23344 
Preeclamptic 0.32296 4.05 ± 0.37220 
Maternal 
Normal 0.27042 4.86 ± 0.53226 
0.82927 
Preeclamptic 0.27534 4.78 ± 0.22279 
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Oxidative stress in normal- and preeclamptic placental tissue 
The oxidative stress of the tissue samples was determined by measuring the MDA content in 
the placental tissue samples. After the reaction with TBA, OD532 of each sample was compared 
to the standard curve of MDA. 
The standard curve of MDA content was prepared by measuring the OD532 of known MDA 
content, ranging from 0 to 20 nM after the reaction with TBA. The oxidative stress of the tissue 
samples are expressed as the MDA content guided by the standard curve as shown in 
Figure 22.  
 
Figure 22: The standard curve for malondialdehyde (MDA). Results are expressed as mean of two independent 
measurements. By using linear regression, the equation of the line is y=0.0674x-0.1557 and the regression coefficient (R2) 
for the line is 0.96. The standard curve was used to determine the amount of MDA in the placental tissue samples using 
the average optical density at 532 nm wavelength for the two independent measurements for each sample. 
Table 22 shows the average OD532, MDA content in nM/mg placental tissue and p-value for 
the normal- and preeclamptic tissue samples, both the maternal- and fetal side. The average 
OD532 was used to calculate the average MDA content in the placental tissue samples using 
the standard curve for MDA content. There is no significant difference between the MDA 
content in the normal- and preeclamptic samples, neither on the maternal- or the fetal side.  
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Table 22: Oxidative stress expressed as the MDA concentration in normal- and preeclamptic placental tissue samples. 
Results are presented as the mean ± standard deviation (SD) of the three normal- and preeclamptic samples, where each 
sample had two independent measurements. 
Side Sample Average OD532 
Oxidative stress (nM 
MDA/mg placental 
tissue) ± SD 
p-value 
Fetal  
Normal 0.435 8.77 ± 0.932 
0.113 
Preeclamptic 0.521 10.03 ± 0.543 
Maternal  
Normal 0.407 8.35 ± 0.704 
0.735 
Preeclamptic 0.430 8.70 ± 1.516 
Discussion 
Clinical parameters 
Mean arterial pressure (MAP) and arterial cord blood Base Excess had a significant 
difference (p=0.014) between the two groups. MAP was measured prior to labour or 
caesarean section and was significantly higher in the women with PE compared to the normal 
women. This observation agrees with the main theory of PE saying that expansion of the spiral 
arteries diameter by the extravillous trophoblasts are incomplete (21). 
Arterial blood pressure base excess was the only parameter with a significant 
difference (p=0.048) between the umbilical cords from normal- and preeclamptic placentas. 
The umbilical cord has three blood vessels: one large vein transporting oxygenated blood to 
the fetus, and two smaller arteries transporting deoxygenated blood and other metabolic 
waste products from the fetus (71). Venous cord blood reflects the combined effect of the 
maternal acid-base status. Maternal factors as hypertension may lead to decreased uterine 
blood flow. Uteroplacental factors as placental infarction or dysfunction may also cause 
abnormal fetal oxygenation during labour (65). The pH, base excess and pCO2 (acid-base 
status) of arterial blood flowing through the umbilical cord provides valuable objective 
evidence of the metabolic condition of neonates at birth. 
The number of caesarean sections were significantly higher (p=0.000) in the preeclamptic 
group compared to the normal group. This is as expected since PE usually occurs preterm, 
meaning the fetus is not fully developed. Therefore, the pregnancy is maintained as long as 
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possible to enhance the fetal outcome (65). Caesarean sections are therefore performed 
when the maternal condition is critical, as the only current cure for PE is removal of the 
placenta. 
Other measured clinical patient parameters did not show a significance difference (p≥0.05), 
neither between the mothers nor the neonates. However, there was expected to be 
significant differences in e.g. BMI, maternal age and nulliparous, as these factors are thought 
to increase the prevalence of PE (6). Because proteinuria is one of the first signs of PE, the 
urine of the women in the normal control group were not analysed as they had no signs of 
proteinuria in their routine controls. 
Implementation and optimisation of methods for morphology 
studies 
The resolution of SIM is 100 nm compared to 50 pm in the transmission electron 
microscope (TEM) (63, 72). SIM is a versatile method where many fluorophores may be used 
in one experiment, allowing a detailed analysis of one section (63). TEM on the other hand, 
only allows using a few different sized gold labelled particles in one section (72). Also, high-
resolution fluorescent microscopy as SIM is a cheaper and quicker method to perform than 
TEM. 
In 2018, a Master project were conducted at the Optical Nanoscopy Research Group, 
comparing the image quality of cryo-sections and formalin-fixed paraffin-embedded (FFPE) 
sections from liver tissue using high-resolution microscopy (73). The previous Master project 
found that ultrathin cryo-sections allow better contrast images compared to FFPE sections. 
There are at least two reasons for this; first, cryo-sections are generally thinner than FFPE 
sections, leading to less out-of-focus information. Second, cryopreservation allows for 
ultrastructural preservation and better antigen accessibility for fluorescent markers as 
compared to FFPE samples (74). In addition to these findings, cryo-sections are easier and 
more time effective to label as it is not necessary to first embed the tissue piece in paraffin, 
followed by deparaffinisation steps prior to labelling. Because of this, cryo-sections were used 
in favour of FFPE in this thesis. 
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Prior to this study, no established protocol for collection and preservation of placental tissue 
for high-resolution microscopy of cryo-sections existed. The collection and fixation protocol 
were based on knowledge of fluorescent- and electron microscopy of placental and other 
tissues. This was used to further optimise the protocol for cryopreservation of placenta for 
high-resolution microscopy. First, fixation was performed following two different approaches; 
one using glutaraldehyde and formaldehyde, and one using only formaldehyde. Sections 
preserved using the fixative containing both glutaraldehyde and formaldehyde were not as 
evenly stained as the sections preserved in the fixative containing only formaldehyde. 
Therefore, the fixative containing only formaldehyde was used. 
Placental tissue has chorion villi submersed in the maternal blood in the intervillous 
space (75). Bernhard and Virion found in 1971 that tissues are better preserved when it is 
immersed in gelatine (76). This coincides with our previous experience from other collection 
and preservation protocols. When the tissue is immersed in gelatine, cavities are filled, and 
the tissue is prevented from collapsing.  Placental tissue samples that were used in the 
previous Master project were not immersed in gelatine prior to freezing, resulting in a 
distorted placental morphology. Also, the previously cryo-preserved tissues were fixed using 
various fixatives, making implementation of a labelling protocol difficult. Implementation of a 
protocol was difficult as there are many various parameters to optimise. 
In the previous Master study, it was found that cryo-sections did not adhere to the cover glass 
during the washing and labelling steps when it was not coated with poly-L-lysine (73). 
Therefore, only poly-L-lysine coated cover glasses were used in this study. The method used 
to label cryo-sections from liver in the previous Master project, and experience with labelling 
procedure of FFPE sections and sections for electron microscopy was used as basis for the 
optimised labelling method of placental cryo-sections. First, the methyl cellulose was not fully 
removed, leading to it being a hazy layer over parts of the sections, making it difficult to focus 
in the microscope. The methyl cellulose residues also lead to an unsuccessful labelling with 
CMO and DAPI. As a solution, the poly-L-lysine coated cover glasses with the cryo-sections 
were cooled down on a metal plate prior to washing, leading to an easier removal of the 
methyl cellulose and cryo-sections that were better labelled. Still, some autofluorescence that 
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might affect the imaging were detected. Because of this, the blocking solution was changed 
from normal goat serum (1 %) to BSA (1 %). Thereafter, the optimal concentration of CMO 
and DAPI were found by labelling different sections with different concentrations of CMO and 
DAPI. At initial phases of the study, it was also discovered that some parts of the sections were 
in focus whereas other parts were not. To ensure correct flatness of the focal plate, a six-
edged nut was placed on top of the cover glasses while the mounting medium hardened. 
During this study, there has been made attempts to label the cryo-sections with antibodies. 
Two trophoblast-specific antibodies were chosen: laeverin and HLA-G antibody (77, 78). 
Different batches of both primary- and secondary antibodies were used without success. 
Further investigations and optimisations are needed to successfully label cryo-sections with 
antibodies. For later experiments, longer incubation time for the primary antibody, using a 
different blocking solution and higher concentrations of the antibodies can be tested. 
Morphological investigation using high-resolution microscopy 
As shown in Figure 9 and Figure 10, neither sections from normal or preeclamptic placentas 
showed significant autofluorescence values that could affect or interfere with imaging of the 
stained sections. 
Because SIM has a higher resolution than deconvolution, SIM was used for morphological 
analysis (63). All normal- and preeclamptic sections confirm the expected morphology of 
placental tissue, having symmetrical nuclei and uniform staining with both CMO and DAPI, 
indicating that the tissue was well preserved and that suitable concentrations of CMO and 
DAPI were used. Comparison of normal- and preeclamptic cryo-sections within the group 
disclosed that sections from all patients had the same structures. However, one patient had 
early PE and the labour was induced preterm (gestational week 27+3). Therefore, the 
structures less developed in these tissues. 
A series of artefacts were discovered during this study, which could have been introduced 
during sectioning, preparation of the sections or microscopy. Some sections had stripes 
occurring from notches in the knife used to section the tissue sample and are not presented 
in the thesis. When these stripes affected the ability of analysing the images, new sections 
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were made. Virtually all sections had some folds, some more than others. This occurred after 
sectioning, when the tissue section was transferred to the poly-L-lysine-coated cover glass. 
The folded regions were not used for investigative purposes and are therefore not presented 
in the thesis. Sections with too much folds were discarded and replaced by new sections. 
During preparation, the ultrathin cryo-sections are invisible to the naked eye, making it 
impossible to inspect them during the various washing and labelling steps of the preparation. 
In cases were the section was accidentally touched with absorbent paper, tears and rifts may 
occur, affecting the overall morphology of the tissue, thus, requiring new sections to be made.  
Artefacts can be introduced during microscopy, such as oil mismatch. It was ensured that oil 
mismatch did not occur by checking the PSF in the orthogonal view of the software, to see 
whether symmetrical shapes occurred (Figure 6). If unsymmetrical shapes occurred, the oil 
was changed accordingly. In addition, some sections may be unevenly placed on the cover 
glass, leading to some structures being in focus, whereas other structures are not in focus. As 
the overall aim of the thesis was to implement a method for high-resolution microscopy of 
placental cryo-sections, the structures were not quantified. Prolonged exposure of light on 
the samples leads to photobleaching of the fluorophores and results in diminishing 
fluorescence. This occurred with the sample of the normal section from the maternal side 
presented Figure 18A and B. When the section was imaged in the fluorescence microscope 
(Figure 17B), maternal capillaries were visualised, whereas when the same region was imaged 
using SIM, the maternal capillaries could not be visualised (Figure 18A and B). 
On the fetal side, the same structures were visualised in both the normal- and preeclamptic 
samples (Table 19). In both the normal- and preeclamptic fetal sections, the 
syncytiotrophoblasts were evenly spread in the syncytium. All sections used for analysing 
purposes were uniformly stained. 
Bright red structures in the cytoplasm are seen in all preeclamptic sections on the fetal 
side (Figure 16B), but are not found in the normal sections from the fetal side (Figure 13B). 
Their size range from 100 nm to 500 nm in diameter; they might be EVs, according to their 
size (79). Organelles such as mitochondria are excluded since they have a diameter ranging 
between 0.5-1 µm (80). Previous studies have shown an abundance of trophoblastic 
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fragments, vesicles and cell free DNA and RNA in the maternal circulation during 
pregnancy (81). Compared to normal pregnancies, more are shed into the maternal circulation 
in PE (50, 81). The presumed EVs found in this study may be a biomarker of PE, and thus need 
to be investigated further with EV specific markers like vascular endothelial growth factor 
receptor 1 (Flt-1) and endoglin (82). 
When comparing the fetal side of the normal- and preeclamptic samples, it may seem to be 
more syncytial knots in the preeclamptic samples. Syncytial knots are a cluster of syncytial 
nuclei on the outer surface of a placental villi and a sign of syncytial damage, occurring when 
syncytial nuclei progress to apoptosis and aggregates (83). Such morphological changes in 
syncytiotrophoblasts may lead to reduction of the placental barrier, allowing leakage of fetal 
antigen into maternal circulation, thus, increasing the immune response and expose the fetus 
to harmful agents (84). Previous studies have found that there are two times more syncytial 
knots in placentas from women with PE compared to normal women (85). Fragments of the 
syncytial knots can be shed into the intervillous space and enter the maternal circulation. The 
number of syncytial knots increases with gestational age (86). Therefore, a morphological 
comparison of normal- and preeclamptic placentas should be carried out in women with the 
same gestational age at delivery. 
On the maternal side, extravillous trophoblasts, syncytiotrophoblasts and both maternal and 
fetal capillaries were identified (Table 20). The maternal side of the normal- and preeclamptic 
sections show similar morphology. It appears to be more scattered nuclei in the normal 
sections in general than the preeclamptic sections. The scattered nuclei may be extravillous 
trophoblasts as they are surrounded by a thicker cell membrane, containing glycocalyx, than 
other trophoblastic cells (87). However, to confirm this hypothesis, extravillous trophoblast-
specific marker must be used. Extravillous trophoblasts are differentiated trophoblasts that 
invade the decidua during the second trimester, increasing the diameter of the maternal 
arteries supplying the placenta with maternal blood, thereby adapting to the nutritional needs 
of the growing fetus (20).  
No maternal capillaries were identified in the preeclamptic sections from the maternal side, 
making a comparison impossible. The reason for this may be because the prepared sections 
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originate from the outer rim towards the fetal side of the collected tissue piece. Therefore, 
maternal capillaries can appear when more sections from parts deeper into the maternal side 
are prepared. For the same reason, fetal capillaries and parts of fetal villi such as 
syncytiotrophoblasts appears in some of the maternal sections as well. It is impossible to 
ensure that the orientation of each section is equal and achieve the same structures. There 
are also individual differences between women. However, individual differences were not 
observed in this study, probably because of a low number of samples. Also, if more markers 
are used to label the sections, individual differences in and between the normal- and 
preeclamptic group are easier to detect. 
Even though all the samples were collected at approximately the same distance from the 
umbilical cord, the pieces that are stored are very small and are randomly selected for 
sectioning. In a larger study, more sections from each patient could be prepared, increasing 
the possibility to visualise more structures and detect differences between the groups. The 
women included in the study should also have been matched for gestational age to ensure 
approximately equal development of the placenta. As the primary aim was to implement a 
method for collection, preservation and labelling, a limited number of sections were prepared 
for morphological analysis when the method was optimised. 
Total antioxidant capacity and oxidative stress study 
To our knowledge, neither the method used to measure TAC or MDA have previously been 
used on placental tissue. Therefore, normal values are not established. Three parallels were 
used in the TAC assay, whereas two parallels were used in the MDA assay. In both assays, all 
measurements were stable (Appendix B and C). Because of this, the method seemed to work 
on placental tissue. 
The TAC assay measures the tissue’s ability of ROS elimination. All tissues have some 
antioxidative micronutrients such as vitamin C and vitamin E that eliminate ROS (88). 
Antioxidants scavenge ROS, meaning the more antioxidants in the tissue, the higher 
antioxidant capacity and higher rate of ROS elimination (30). In this study, there was no 
significant difference (p≥0.05) between the TAC of normal- and preeclamptic placental tissue. 
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However, the TAC of the normal tissue samples show a trend of being generally higher than 
the preeclamptic, both for the fetal and the maternal side (Table 21). 
The MDA assay measures the MDA content of the samples. MDA is a product of lipid 
peroxidation after reacting with ROS, which occurs by oxidative stress. Therefore, a higher 
MDA value reflects an increased oxidative stress level in the tissue, whereas a lower MDA 
value reflects a lower oxidative stress level in the tissue. Although there was no significant 
difference (p≥0.05) between the normal- and preeclamptic tissue samples, there was a trend 
of the MDA content being higher in the preeclamptic samples, both for the fetal and maternal 
side (Table 22). 
The oxidative stress and the TAC of a tissue is closely connected. It is found that pregnant 
women in general have increased levels of MDA compared to non-pregnant women (30). Also, 
previous studies have found that the TAC of preeclamptic placentas are lower than the TAC of 
normal placentas (89, 90). The TAC of the placental tissue in normal pregnant women 
increases as the oxidative stress in the tissue increases, thereby eliminating ROS and prevent 
increased oxidative stress (30). Pregnant women with PE have higher levels of MDA than 
normal pregnant women with the same gestational age, meaning this adaptation of the TAC 
does not occur in pregnant women with PE, leading to oxidative stress (30, 31). Since other 
studies have found that there is a significant difference in the TAC and MDA content between 
normal- and preeclamptic samples, the difference is probably found if more patients are 
included in the study. 
Conclusions 
The implemented protocol for collection and staining of placental tissue is well suited for 
investigating placental morphology using high-resolution microscopy, as the placental 
morphology is preserved, and the sections are evenly stained. The method is cheaper, more 
rapid and easier than TEM. In preeclamptic sections, there seemed to be more syncytial knots 
than in normal sections, in addition to bright red structures that may be EVs which were not 
found in normal sections. The methods used to determine TAC and MDA content can also be 
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used on placental tissue. No significant difference was found between the TAC and oxidative 
stress levels of normal- and preeclamptic placentas.  
Future perspectives 
The current method for sample preparation is well suited for high-resolution microscopy. 
However, the method should be further developed to include labelling of specific proteins, 
cell structures and cell types with antibody-conjugated fluorophores. This allows a more 
thorough investigation of placental morphology. By labelling more structures, morphological 
differences between normal- and preeclamptic placentas can be more easily detected and 
different subsets of placental cells can be identified. In addition, quantitative studies 
comparing the amount of EVs and syncytial knots may be performed on tissue sections from 
placentas of normal pregnancies and placentas from women with PE. 
If the detected bright red structures are EVs, these are presumably secreted into the maternal 
circulation. To investigate whether this is the case, liquid biopsies from the maternal 
circulation can be performed. An advantage with this approach is that it is non-invasive and 
can be performed throughout the pregnancy. This approach can also be extended to include 
other biomarkers thought to be related to PE, such as microRNA, proteins and cell free fetal 
DNA. Over time, this result in the possibility of detecting pregnancies at risk of being affected 
with PE prior to disease onset. 
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Appendix A: Consent form 
A consent form was given to the pregnant women in Norwegian to ensure that they 
understood what they consented to. This form is translated and contains the same 
information that was given to the women.  
Preeclampsia is a disease affecting pregnant women with an incidence of 8-10 % worldwide 
and 4 % in Norway. The disease is potentially life-threatening disease for both the mother and 
her unborn child. Women with the condition have high blood pressure, proteins in their urine, 
edemas in the body and may affect different organs. The placenta has an important role in 
the development of preeclampsia. The aim of this pilot study is to implement high-resolution 
microscopy of placental tissue as an analytic tool used in diagnostic and research.  
I consent that information from conversations and examination during pregnancy, in addition 
to examination of placental tissue, can be registered and used for research. 
The collected material can be used for necessary research with the purpose of finding new 
biological and medical knowledge regarding preeclampsia. I am aware that it takes a long time 
to find all important factors and therefore, there is no set end-date for this research project. 
 I confirm that sufficient information has been given regarding the use of data and what will 
be stored. I know that no data from this research can be linked to my name, that my 
participation is voluntary, and that my consent can be withdrawn at any point without 
specifying a reason. I am informed that this research requires approval from Datatilsynet and 
the Ethical committee, and that questions can be directed to the doctor, researcher or 
midwife that invited to participate in the study. 
Yes, I consent to research …………………………………………………………………… 
                                                                                                          (date, signature) 
No, I do not consent to research …………………………………………………………………… 





Appendix B: Raw data, total antioxidant capacity assay 
 
# Name Abs<730nm>  # Name Abs<730nm> 
1 Vit C 0 0.60717  30 2P-F 0.33192 
2 Vit C 0 0.61291  31 2P-M 0.30345 
3 Vit C 0 0.61908  32 2P-M 0.27094 
4 Vit C 1 0.52748  33 2P-M 0.27909 
5 Vit C 1 0.51878  34 3P-F 0.31446 
6 Vit C 1 0.53769  35 3P-F 0.29080 
7 Vit C 2 0.45761  36 3P-F 0.29514 
8 Vit C 2 0.46185  37 3P-M 0.26657 
9 Vit C 2 0.46152  38 3P-M 0.24578 
10 Vit C 4 0.30982  39 3P-M 0.26322 
11 Vit C 4 0.30459  40 1N-F 0.32305 
12 Vit C 4 0.30557  41 1N-F 0.33059 
13 Vit C 6 0.15824  42 1N-F 0.33048 
14 Vit C 6 0.17039  43 1N-M 0.28997 
15 Vit C 6 0.16284  44 1N-M 0.28108 
16 Vit C 8 1.3879E-2  45 1N-M 0.28783 
17 Vit C 8 1.4417E-2  46 2N-F 0.25083 
18 Vit C 8 2.6336E-2  47 2N-F 0.25002 
19 Vit C 10 -2.5172E-3  48 2N-F 0.25396 
20 Vit C 10 -3.2301E-3  49 2N-M 0.22071 
21 Vit C 10 -2.1305E-3  50 2N-M 0.23843 
22 1P-F 0.32695  51 2N-M 0.23233 
23 1P-F 0.31905  52 3N-F 0.27886 
24 1P-F 0.31412  53 3N-F 0.27354 
25 1P-M 0.29078  54 3N-F 0.28473 
26 1P-M 0.27816  55 3N-M 0.29954 
27 1P-M 0.28004  56 3N-M 0.29194 
28 2P-F 0.36071  57 3N-M 0.29193 




Appendix C: Raw data, oxidative stress assay 
Table 23: Layout and raw data for the oxidative stress assay. The first line in each square denotes the type of sample, whereas the second line is the measured optical density at 532 nm 
wavelength (OD532) for the sample. Each sample was measured in two parallels. 
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